Recently, it was shown that ML-385 reduced the expression of NRF2 and simultaneously induced the expression of its inhibitor KEAP1 in NSCLC cells with KEAP1 loss-of-function mutations [40]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.